Atlas Ventures

The firms announced a deal to identify strategic investments in technology areas within agriculture "to support and complement Monsanto's interests and potential growth areas."

The startup has now raised a total of $26 million in Series A financing to support development of a biomarker-based cancer diagnostic.

The new preliminary prospectus offers for sale around 9.6 million shares by shareholders of the firm. Helicos won't receive any proceeds from the sale.

Short Reads

Premium

Life Technologies, Max Planck Institute for Evolutionary Anthropology, 454 Life Sciences, Applied Biosystems, Baylor College of Medicine, University of Bristol, University of Liverpool, John Innes Centre, Helicos BioSciences, Febit, and more…

Helicos filed the prospectus for 68.4 million shares held by investors who participated in a private placement in December. The firm would receive none of the proceeds from the sale of those shares, if any of them are sold.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.